Trulicity vs Ozempic: Mechanism, Weight Loss, Side Effects, Cost

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with Eli Lilly or Novo Nordisk.

Trulicity and Ozempic are two of the most-searched GLP-1 receptor agonists in the U.S. as of April 2026. They share a drug class but differ in their active ingredients, dosing schedules, FDA-approved indications, and clinical trial populations. This article compares the two head-to-head on mechanism, evidence, safety, cost, and access — plus the upstream genetic variables that apply regardless of which compound a provider prescribes.

Side-by-side mechanism

Trulicity (dulaglutide, Eli Lilly) is a long-acting GLP-1 receptor agonist engineered as a fusion protein — human GLP-1 sequences linked to a modified IgG4 Fc fragment, which extends the half-life and enables once-weekly dosing. Ozempic (semaglutide, Novo Nordisk) is a selective GLP-1 receptor agonist whose backbone is modified with a fatty acid side chain that binds albumin, also enabling once-weekly dosing. Both compounds engage the GLP-1 receptor in the pancreas, hypothalamus, and gastrointestinal tract — slowing gastric emptying, blunting post-meal glucose excursions, and increasing satiety signaling.

FDA status and approved indications

Trulicity was FDA-approved in 2014 for type 2 diabetes and in 2020 received an added indication to reduce major adverse cardiovascular events in adults with type 2 diabetes. Ozempic was FDA-approved in 2017 for type 2 diabetes, with a later cardiovascular outcomes indication. Neither is FDA-approved for chronic weight management as a branded indication — Wegovy (semaglutide 2.4 mg) is the Novo Nordisk weight-management brand of semaglutide, while Trulicity remains diabetes-only on its label.

Weight loss and A1C evidence

Head-to-head data exists: the SUSTAIN 7 trial compared semaglutide 1.0 mg weekly against dulaglutide 1.5 mg weekly in type 2 diabetes — semaglutide showed larger mean A1C reduction and larger mean body-weight reduction in that trial (as published in The Lancet Diabetes & Endocrinology, 2018). Ozempic's dosing later expanded to 2.0 mg weekly for diabetes, outside the SUSTAIN 7 range. Trial populations and dosing differ across the broader SUSTAIN and AWARD programs, so individual outcomes vary and the cleanest read is per-trial.

Side effects and safety

Both Trulicity and Ozempic carry the GLP-1 class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The most common side effects across both products are gastrointestinal: nausea, vomiting, diarrhea, constipation. Serious adverse events reported in both classes include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

Cost and access

Trulicity list price is approximately $1,064 per month at U.S. list price as of April 2026 (Eli Lilly published pricing). Ozempic list price is approximately $968–$1,029 per month at U.S. list price as of April 2026 (Novo Nordisk published pricing). Out-of-pocket cost depends heavily on insurance coverage, the FDA indication for which the prescription is written, manufacturer savings card eligibility, and whether a compounded alternative is available through a licensed compounding pharmacy pathway. See the PlexusDx reviews of Trulicity savings options and Ozempic cost in 2026 for the current savings-program landscape.

The overlapping genetic variables

Whichever compound a clinician ultimately prescribes, the upstream genetic architecture is shared. Variants in FTO (the fat-mass and obesity-associated gene — common variants influence appetite regulation and adiposity set-point), GLP1R (the gene encoding the GLP-1 receptor that both compounds engage), and MC4R (a melanocortin receptor gene central to energy balance and satiety) shape the baseline metabolic terrain on which any GLP-1 receptor agonist has to work. These variants are pathway-level; they do not predict response to any one compound, but they do map the biology a clinician is prescribing into.

PlexusDx offers semaglutide through its Weight Management Protocols — available as Semaglutide Injection and Semaglutide Oral formats. PlexusDx does not sell, distribute, or prescribe dulaglutide. Regardless of which GLP-1 pathway compound you and your healthcare provider eventually discuss, the underlying genetic architecture is the same. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile before committing to any protocol is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: Ozempic Drug, Ozempic Uses, Novo Nordisk Ozempic, Ozempic Strength.

Disclaimer: This article is educational. PlexusDx offers semaglutide through its Weight Management Protocols. PlexusDx does not sell, prescribe, or recommend dulaglutide. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols — semaglutide and tirzepatide with the genetic context most providers don't offer. Or start upstream: take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

How does Trulicity differ from Ozempic mechanically?

Trulicity (dulaglutide) is a fusion protein linking GLP-1 sequences to a modified IgG4 Fc fragment. Ozempic (semaglutide) is a modified peptide bound to albumin via a fatty-acid side chain. Both engage the GLP-1 receptor once weekly, but the structural designs differ — which is relevant to immunogenicity and half-life profiles.

Which is more effective for weight loss?

In the SUSTAIN 7 head-to-head trial, semaglutide 1.0 mg weekly produced greater mean body-weight reduction than dulaglutide 1.5 mg weekly at 40 weeks in type 2 diabetes. Neither compound is FDA-approved for weight management as-labeled — Wegovy (semaglutide 2.4 mg) is the weight-management brand. Outcomes vary; discuss individual context with a provider.

Can genetic testing predict which is right for me?

No. The Precision Peptide Genetic Test does not predict response to Trulicity, Ozempic, or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and related genes that shape baseline GLP-1, appetite, and energy-balance biology — the upstream variable that applies across both compounds and every GLP-1 receptor agonist.

Are the side effects different?

Side-effect profiles are broadly similar across the GLP-1 class: nausea, vomiting, diarrhea, and constipation are most common, typically most pronounced during dose escalation. Both carry the class-wide boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis and gallbladder disease.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education